Here’s Why BioTechne (TECH) Traded Lower in Q3

Core Insights - The Mairs & Power Balanced Fund reported a return of 6.47% in the first nine months of 2025, underperforming benchmark indexes which increased by 11.35% and 10.73% respectively [1] - The market remains concentrated with a few mega-cap stocks related to artificial intelligence driving most favorable outcomes [1] Company Performance - Bio-Techne Corporation (NASDAQ:TECH) has a market capitalization of $9.478 billion and focuses on life science reagents, instruments, and services [2] - The one-month return for Bio-Techne was 0.13%, but it experienced a significant decline of 20.67% over the past 52 weeks, closing at $60.83 per share on December 10, 2025 [2] - In the fiscal first quarter of 2026, Bio-Techne generated revenues of $286.6 million, reflecting a 1% year-over-year decline on both an organic and reported basis [4] Fund Strategy and Sector Exposure - The fund's overweight position in Health Care, particularly in Bio-Techne, negatively impacted its relative performance in the first nine months of 2025 due to uncertainties in the biopharmaceutical funding environment [3] - The fund has taken advantage of recent weaknesses in Bio-Techne to increase its holdings in the company [3] - Despite acknowledging Bio-Techne's potential, the fund believes that certain AI stocks present greater upside potential with less downside risk [4] Hedge Fund Interest - Bio-Techne was held by 43 hedge fund portfolios at the end of the third quarter, an increase from 37 in the previous quarter [4]